Search Protocols under revision. Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupEndocrine and Neuroendocrine OncologyThoracic TumorsTumor, regardless of entityDiseaseLung Carcinoma, Non-Small CellThyroid CancerTumor Biomarker DefinedSubgroupRET fusion positiveICD10C34.-C73MeSHCarcinoma, Non-Small-Cell LungThyroid NeoplasmsSequenceChemotherapyChemo-substanceSelpercatinibChemo-substanceSelpercatinibChemo-substanceSelpercatinibChemo-substanceSelpercatinibNo. Substances1 RadiotherapySupportive therapySupportive substanceSupportive substanceSupportive substanceSupportive substanceNo. SubstancesProtocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentioncurativepalliativeRisksConstipationDiarrheaEmetogenicityHepatotoxicityHypertensionIncrease AminotransferasesPyrexiaQTc Time ExtensionRashThrombocytopenia below 50 000/µl only studiesPublicationAuthorDrilon AWu YDiseaseNichtkleinzelliges Lungenkarzinom, RET+, Stadium IB-IIIA, Erstlinie, adjuvant, ECOG 0-1RET-bedingte Tumoren, Zweitlinie oder höher, ECOG 0-2OriginMemorial Sloan Kettering Cancer Center and Weill Cornell Medical College, LIBRETTO-001Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, LIBRETTO-432Protocols in Revision 2 protocols foundSelpercatinib 160, Non-Small Cell Lung Cancer, adjuvant (PID3231 V1.0)Selpercatinib 160, Tumor Biomarker Defined (PID1732 V1.0)
